Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer
24 mars 2020 08h25 HE
|
Exagen, Inc.
SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced...
Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease
16 mars 2020 08h19 HE
|
Exagen, Inc.
SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...
Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management
22 nov. 2019 08h25 HE
|
Exagen, Inc.
SAN DIEGO, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Exagen Inc. Announces $26.2 Million Debt Refinancing
21 nov. 2019 08h25 HE
|
Exagen, Inc.
SAN DIEGO, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...
Exagen Inc. to Participate in the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019
20 nov. 2019 05h15 HE
|
Exagen, Inc.
SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
AVISE® MTX Test from Exagen Supports Horizon Therapeutics plc Clinical Trial to Evaluate Pegloticase with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
24 oct. 2019 08h20 HE
|
Exagen, Inc.
SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), is pleased to announce clinical study support for Horizon Therapeutics plc (Nasdaq: HZNP) to measure methotrexate...
Exagen Announces Publication of Two Key Studies Validating Clinical Performance of AVISE® Lupus in Patients with Probable SLE and Demonstrating Superior Clinical Utility Compared to Standard Diagnostic Testing
15 oct. 2019 08h15 HE
|
Exagen, Inc.
SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Exagen Inc. Announces Pricing of Initial Public Offering
18 sept. 2019 19h14 HE
|
Exagen Inc.
San Diego, CA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...
Exagen Announces Launch of Novel Biomarker PC4d Associated with Thrombosis in Lupus
12 oct. 2018 10h01 HE
|
Exagen Diagnostics, Inc.
ALBUQUERQUE, NM and SAN DIEGO, CA, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life sciences, announced today that it will be updating the popular AVISE® SLE Monitor...
Exagen Featured in Eight Scientific Presentations at The 2018 ACR/ARHP Annual Meeting in Chicago, IL
02 oct. 2018 08h47 HE
|
Exagen Diagnostics, Inc.
ALBUQUERQUE, NM and SAN DIEGO, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, the exclusive providers of AVISE® testing, announced today that a total of eight scientific presentations...